Want to see IN:ZYDUSLIFE full AI Analyst Report?
Top Page
Zydus Lifesciences Limited
(ZYDUSLIFE)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹1,148.00
▲(3.53% Upside)
Action:Reiterated
Date:08/21/26
The score is primarily held back by fundamentals: a sharp 2026 drop in operating cash flow and negative free cash flow, along with a rapid increase in leverage, outweigh otherwise solid revenue growth and healthy profitability. Technical signals are neutral-to-weak, and valuation offers limited support given a ~24.7 P/E and very low dividend yield.
Positive Factors
Revenue Growth
Sustained multi-year revenue expansion indicates continued product demand and market reach. This provides a durable growth base across domestic and international pharmaceutical markets, even if individual products face competition.
Negative Factors
Rapid Leverage Increase
The sharp increase in leverage materially reduces financial flexibility compared with prior years. Higher debt can increase financing requirements and constrain investment capacity if operating margins or cash generation remain volatile.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year revenue expansion indicates continued product demand and market reach. This provides a durable growth base across domestic and international pharmaceutical markets, even if individual products face competition.
Read all positive factors
Zydus Lifesciences Limited (ZYDUSLIFE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.14T
Dividend Yield0.09%
Average Volume (3M)85.24K
Price to Earnings (P/E)25.5
Beta (1Y)0.50
Revenue Growth21.11%
EPS Growth-1.28%
CountryIN
Employees29,980
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)44.87
Shares Outstanding997,503,850
10 Day Avg. Volume100,269
30 Day Avg. Volume85,240
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)3.23
Price to Sales (P/S)3.23
P/FCF Ratio-72.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,240.00Price Target Upside11.82% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)40.63
Revenue Forecast (FY)₹317.57B
Zydus Lifesciences Limited Business Overview & Revenue Model
Company Description
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of...
How the Company Makes Money
Zydus Lifesciences primarily makes money by selling pharmaceutical and wellness products through a mix of domestic (India) and international markets. Key revenue streams typically include: (1) Formulations (finished dosage medicines): Revenue from...
Zydus Lifesciences Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
62
Positive
Cash Flow
39
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 285.92B | 271.48B | 232.41B | 195.47B | 172.37B | 151.10B |
| Gross Profit | 143.43B | 140.30B | 167.03B | 131.54B | 107.67B | 94.24B |
| EBITDA | 80.97B | 85.65B | 68.30B | 52.57B | 35.34B | 31.70B |
| Net Income | 45.13B | 50.40B | 45.26B | 38.59B | 19.60B | 44.87B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 524.07B | 372.02B | 292.81B | 257.56B | 277.95B |
| Cash, Cash Equivalents and Short-Term Investments | 49.71B | 71.92B | 78.08B | 13.58B | 11.92B | 35.05B |
| Total Debt | 0.00 | 124.96B | 32.13B | 8.04B | 11.95B | 42.21B |
| Total Liabilities | -295.82B | 228.24B | 108.43B | 71.79B | 60.68B | 87.42B |
| Stockholders Equity | 295.82B | 271.11B | 239.53B | 198.29B | 175.16B | 170.00B |
Cash Flow | ||||||
| Free Cash Flow | 785.00M | -12.03B | 50.64B | 23.21B | 16.58B | 9.02B |
| Operating Cash Flow | 9.46B | 21.91B | 67.77B | 32.28B | 26.89B | 21.04B |
| Investing Cash Flow | -51.93B | -87.25B | -83.72B | -14.75B | 11.71B | -10.00B |
| Financing Cash Flow | 40.45B | 61.60B | 20.14B | -17.79B | -44.00B | -8.68B |
Zydus Lifesciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹1.00T | 30.37 | ― | 0.67% | -0.92% | -41.75% | |
69 Neutral | ₹963.76B | 26.20 | ― | 0.24% | 9.09% | 9.61% | |
69 Neutral | ₹927.84B | 16.79 | ― | 0.89% | 28.19% | 49.25% | |
69 Neutral | ₹4.34T | 35.73 | ― | 0.88% | 11.41% | 16.62% | |
63 Neutral | ₹1.81T | 73.98 | ― | 0.31% | 32.85% | 8.94% | |
57 Neutral | ₹1.14T | 25.53 | ― | 0.09% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,138.50
145.09
14.61%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,670.00
573.85
52.35%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,208.00
-32.63
-2.63%
IN:LUPIN
Lupin Limited
2,010.00
85.90
4.46%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,782.00
143.02
8.73%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,755.15
1,260.85
36.08%
Zydus Lifesciences Limited Corporate Events
Zydus Wins USFDA Nod and 180-Day CGT Exclusivity for Ascorbic Acid Injection
Aug 21, 2026
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Ascorbic Acid Injection, a generic version of Ascor Injection used for short-term treatment of scurvy in patient...
Zydus Lifesciences Publishes Q1 FY27 Earnings Call Transcript for Investors
Aug 18, 2026
Zydus Lifesciences Limited is an India-based pharmaceutical and lifesciences company whose shares are listed on BSE Limited and the National Stock Exchange of India. Its core business centers on healthcare and drug products, and the company mainta...
Zydus Lifesciences to Join Motilal Oswal Global Investor Conference 2026
Aug 10, 2026
Zydus Lifesciences Limited has announced that it will participate in the Motilal Oswal 22nd Annual Global Investor Conference on August 18, 2026. Engagement at this high-profile investor forum signals the company’s continued focus on investo...
Zydus Lifesciences launches ₹1,100-crore share buyback via tender offer
May 31, 2026
Zydus Lifesciences Limited has launched a share buyback of up to 8,730,158 fully paid equity shares, each with a face value of INR 1, at a price of INR 1,260 per share, aggregating to an amount not exceeding INR 1,100 crore. The buyback will be ex...
Zydus Lifesciences Publishes Q4 FY26 Earnings Call Transcript for Investors
May 24, 2026
Zydus Lifesciences Limited has released the official transcript of its Q4 FY26 post-results earnings call held on May 19, 2026, in compliance with SEBI’s Listing Obligations and Disclosure Requirements. The document, shared with both BSE and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.